Keros Therapeutics launches $5 million share buyback program

Keros Therapeutics authorized a $5 million share repurchase program following a $20 million elritercept milestone payment from Takeda.

• Buybacks may occur from time to time in the open market or through other permitted methods.
• Repurchase timing and size will depend on share price, market conditions, contractual limits and other factors.
• The program can be modified, suspended or terminated at any time.